<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01559064</url>
  </required_header>
  <id_info>
    <org_study_id>MAF/AGN/MED/FIL/017</org_study_id>
    <nct_id>NCT01559064</nct_id>
  </id_info>
  <brief_title>The Volumizing Effect of Juvéderm VOLUMA® in the Mid-Face</brief_title>
  <official_title>A Prospective, Observational Study of the Volumizing Effect of Open-Label Aesthetic Use of VOLUMA® in the Mid-Face Area</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, observational study of the volumizing effect of aesthetic use of
      Juvéderm VOLUMA® with lidocaine in the mid-face area.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Subject Experience Measured by Patient Satisfaction Questionnaire</measure>
    <time_frame>3 weeks</time_frame>
    <description>Subject satisfaction with treatment, based on a 5-point scale: (1) Delighted, (2) Happy, (3) Neutral, (4) Unhappy, (5) Very Unhappy</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">115</enrollment>
  <condition>Age-related Volume Deficit in the Mid-face</condition>
  <arm_group>
    <arm_group_label>Age group A</arm_group_label>
    <description>Subjects 30 to 40 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age group B</arm_group_label>
    <description>Subjects 40 to 50 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age group C</arm_group_label>
    <description>Subjects over 50 years old</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)</intervention_name>
    <description>All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.</description>
    <arm_group_label>Age group A</arm_group_label>
    <arm_group_label>Age group B</arm_group_label>
    <arm_group_label>Age group C</arm_group_label>
    <other_name>Juvéderm VOLUMA® with lidocaine</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Normal, healthy subjects desiring aesthetic improvement
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Desire and willingness for correction of asymmetry or enhancement of his/her mid-face
             area.

          -  Be willing to undergo treatment for volume loss in the face area

          -  Females and males ≥30 years of age

          -  Be in good health as of the opinion of the Investigator

          -  Sign the Informed Consent Form prior to any study-related procedures being performed

          -  Have established a realistic treatment goal that the Investigator agrees is achievable
             i.e., have realistic expectations of aesthetic results

        Exclusion Criteria:

          -  Have extensive tissue damage that could affect the aesthetic outcome

          -  Have a known allergy to any component of VOLUMA® with lidocaine injections

          -  Have an abscess or infection at the time of treatment that in the opinion of the
             Investigator does not make the subject eligible for the procedure.

          -  Have undergone cosmetic facial [e.g., face-lift, or other surgeries, which may alter
             the appearance of the mid-face region (laser, photomodulation intense pulsed light,
             radio frequency, dermabrasion, moderate or greater depth chemical peel, or other
             ablative procedures), tissue augmentation with dermal fillers or fat injections, or
             meso-therapy] anywhere in the mid-face region, or Botox® Cosmetic injections in the
             lower face (below the orbital rim), within the 6 months prior to entry in the study or
             be planning to undergo any of these procedures at any time during the study. NOTE:
             Prior treatment with hyaluronic acid (HA) fillers and/or collagen is allowed, provided
             the treatment was administered more than 6 months prior to study entry

          -  Have ever received semi-permanent fillers or permanent facial implants, e.g., calcium
             hydroxyapatite, L-polylactic acid, polymethylmethacrylate (PMMA), silicone, expanded
             polytetrafluoroethylene (ePTFE) anywhere in the lips, or be planning to be implanted
             with any of these products at any time during the study

          -  Have a history of anaphylaxis, multiple severe allergies, atopy, allergy to lidocaine
             (or any amide-based anesthetics), HA products, or Streptococcal protein, or be
             planning to undergo a desensitization therapy during the term of the study

          -  Suffer from an uncontrolled personality disorder (e.g., body dysmorphia, depression)

          -  Have a history of or currently suffer from an autoimmune disease (e.g., Rheumatoid
             arthritis, Crohn's disease)

          -  Have a history of streptococcal disease (e.g., strep throat or rheumatic fever with or
             without heart complications)

          -  Have a history of skin cancer

          -  Suffer from Porphyria

          -  Have epilepsy which is not controlled by anti-epilepsy therapy

          -  Current cutaneous inflammatory and/or infectious processes (e.g., acne, herpes, etc.)

          -  Have a history of treatment with interferon therapy (e.g., warfarin) or have taken
             non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin, ibuprofen) or other
             substances known to increase coagulation time (e.g., herbal supplements with garlic or
             ginko biloba) within 10 days of undergoing study device injection. NOTE: Study device
             injection may be delayed as necessary to accommodate this 10-day washout period

          -  Be on a concurrent regimen of high doses of lidocaine (more than 400 mg) which may
             cause acute toxic reactions

          -  Be on a concurrent regimen of other local anesthetics structurally related to
             amide-type local anesthetics

          -  Have impaired cardiac conduction, severly impaired hepatic function, or severe renal
             dysfunction

          -  Have a condition or be in a situation that, in the Investigator's opinion, may put the
             subject at significant risk, may confound the study results, or may interfere
             significantly with the subject's participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Allergan Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koln</city>
        <state>North Rhine-Westphalia</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mere Green</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Philipp-Dormston WG, Eccleston D, De Boulle K, Hilton S, van den Elzen H, Nathan M. A prospective, observational study of the volumizing effect of open-label aesthetic use of Juvéderm® VOLUMA® with Lidocaine in mid-face area. J Cosmet Laser Ther. 2014 Aug;16(4):171-9. doi: 10.3109/14764172.2014.910079. Epub 2014 May 5.</citation>
    <PMID>24689357</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2012</study_first_posted>
  <results_first_submitted>March 21, 2013</results_first_submitted>
  <results_first_submitted_qc>June 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2013</results_first_posted>
  <last_update_submitted>October 6, 2014</last_update_submitted>
  <last_update_submitted_qc>October 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Age Group A</title>
          <description>Subjects 30 to 40 years old
Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®) : All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.</description>
        </group>
        <group group_id="P2">
          <title>Age Group B</title>
          <description>Subjects 40 to 50 years old
Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®) : All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.</description>
        </group>
        <group group_id="P3">
          <title>Age Group C</title>
          <description>Subjects over 50 years old
Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®) : All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Age Group A</title>
          <description>Subjects 30 to 40 years old
Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®) : All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.</description>
        </group>
        <group group_id="B2">
          <title>Age Group B</title>
          <description>Subjects 40 to 50 years old
Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®) : All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.</description>
        </group>
        <group group_id="B3">
          <title>Age Group C</title>
          <description>Subjects over 50 years old
Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®) : All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="59"/>
            <count group_id="B4" value="115"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.7" spread="3.3"/>
                    <measurement group_id="B2" value="45.2" spread="2.8"/>
                    <measurement group_id="B3" value="58.3" spread="5.8"/>
                    <measurement group_id="B4" value="50.6" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject Experience Measured by Patient Satisfaction Questionnaire</title>
        <description>Subject satisfaction with treatment, based on a 5-point scale: (1) Delighted, (2) Happy, (3) Neutral, (4) Unhappy, (5) Very Unhappy</description>
        <time_frame>3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Age Group A</title>
            <description>Subjects 30 to 40 years old
Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®) : All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.</description>
          </group>
          <group group_id="O2">
            <title>Age Group B</title>
            <description>Subjects 40 to 50 years old
Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®) : All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.</description>
          </group>
          <group group_id="O3">
            <title>Age Group C</title>
            <description>Subjects over 50 years old
Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®) : All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Experience Measured by Patient Satisfaction Questionnaire</title>
          <description>Subject satisfaction with treatment, based on a 5-point scale: (1) Delighted, (2) Happy, (3) Neutral, (4) Unhappy, (5) Very Unhappy</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread=".68"/>
                    <measurement group_id="O2" value="1.62" spread=".78"/>
                    <measurement group_id="O3" value="1.51" spread=".57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Age Group A</title>
          <description>Subjects 30 to 40 years old
Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®) : All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.</description>
        </group>
        <group group_id="E2">
          <title>Age Group B</title>
          <description>Subjects 40 to 50 years old
Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®) : All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.</description>
        </group>
        <group group_id="E3">
          <title>Age Group C</title>
          <description>Subjects over 50 years old
Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®) : All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injection site hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Injection site edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Monitor</name_or_title>
      <organization>Allergan, Inc.</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

